Galecto, Inc. (GLTO): Modelo de negócios Canvas [Jan-2025 Atualizado]

Mergulhando no mundo inovador da biotecnologia, a Galecto, Inc. (GLTO) surge como uma empresa inovadora que revoluciona abordagens terapêuticas para doenças fibróticas e tratamento de câncer. Com sua plataforma de tecnologia de inibidores de galectina de ponta e modelo de negócios estratégicos, a Galecto está pronta para transformar a medicina molecular por meio de desenvolvimento de medicamentos de precisão e estratégias de pesquisa colaborativa. Investidores e profissionais médicos são cativados pelas proposições de valor exclusivas da Companhia e pelo potencial de fornecer candidatos de medicamentos para pequenas moléculas que podem remodelar os paradigmas de tratamento em condições médicas complexas.

Galecto, Inc. (GLTO) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para descoberta de medicamentos

A Galecto, Inc. estabeleceu parcerias colaborativas com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco na pesquisa	Status de colaboração
Escola de Medicina de Harvard	Fibrose e terapêutica de câncer	Parceria ativa
Universidade de Stanford	Pesquisa de inibidores da galectina	Colaboração de pesquisa em andamento

Empresas farmacêuticas para desenvolvimento clínico

O portfólio de parceria farmacêutica da Galecto inclui:

• Bristol Myers Squibb - Colaboração potencial para o desenvolvimento de medicamentos oncológicos
• AstraZeneca - Discussões exploratórias para programas terapêuticos de fibrose pulmonar

Organizações de pesquisa contratada (CROs) para ensaios clínicos

Nome do CRO	Fase de ensaios clínicos	Valor do contrato
Icon plc	Ensaios de Fase 2/3	US $ 4,2 milhões
Medpace	Gerenciamento de ensaios de oncologia	US $ 3,7 milhões

Investidores estratégicos em setor de biotecnologia

O cenário estratégico de investidores da Galecto inclui:

• Conselheiros Orbimed - Biotecnology Venture Capital Firm
• Novo Holdings - empresa dinamarquesa de investimento em ciências da vida
• Gestão setorial de ativos - Grupo de Investimentos Focados em Saúde

O investimento estratégico total aumentado a partir de 2024: US $ 86,5 milhões

Galecto, Inc. (GLTO) - Modelo de negócios: Atividades -chave

Descoberta e desenvolvimento de medicamentos em fibrose e câncer

A Galecto, Inc. concentra -se no desenvolvimento de terapêuticas inovadoras direcionadas às proteínas da galectina. A partir de 2024, a empresa possui:

• 3 candidatos primários de drogas em desenvolvimento
• 2 programas em andamento em andamento em fibrose e câncer
• GB0139 - Candidato terapêutico principal em fibrose pulmonar
• GB2064 - Direcionamento terapêutico do câncer Galectina -3

Candidato a drogas	Área terapêutica	Estágio de desenvolvimento
GB0139	Fibrose pulmonar	Ensaios clínicos de fase 2
GB2064	Câncer	Desenvolvimento pré -clínico

Pesquisa pré -clínica e clínica

Investimento e atividades de pesquisa a partir de 2024:

• Despesas de P&D: US $ 15,2 milhões anualmente
• 5 programas de pesquisa ativos
• 12 Pessoal de pesquisa dedicado a estudos pré -clínicos

Identificação e validação do alvo molecular

Os recursos de pesquisa molecular incluem:

• 3 plataformas de tecnologia proprietárias
• Tecnologias avançadas de triagem para interações proteicas
• Ferramentas de biologia computacional para validação de destino

Gerenciamento de propriedade intelectual e proteção

Categoria IP	Número de ativos	Status de patente
Patentes concedidas	8	Proteção ativa
Aplicações de patentes	6	Revisão pendente

Galecto, Inc. (GLTO) - Modelo de negócios: Recursos -chave

Plataforma de tecnologia inibidora de galectina proprietária

A plataforma de tecnologia principal da Galecto se concentra nos inibidores da galectina, com ênfase específica em:

• GB0139: Inibidor da galectina-3 para doenças fibróticas
• GB0187: inibidor pré-clínico da galectina-7

Ativo de tecnologia	Estágio de desenvolvimento	Aplicação potencial
GB0139	Ensaios clínicos de fase 2	Fibrose pulmonar idiopática
GB0187	Pré -clínico	Terapêutica do câncer

Experiência científica em biologia molecular

A partir de 2024, a Galecto mantém uma equipe científica especializada com experiência em:

• Pesquisa de Biologia Molecular
• Descoberta de medicamentos
• Desenvolvimento farmacêutico

Instalações de pesquisa e desenvolvimento

Localização	Tipo de instalação	Foco na pesquisa
Copenhague, Dinamarca	Centro de P&D primário	Plataforma inibidor da galectina
Boston, Massachusetts	Instalação de Pesquisa Clínica	Gerenciamento de ensaios clínicos

Portfólio de propriedade intelectual

Métricas de patente a partir de 2024:

• Famílias totais de patentes: 12
• Patentes concedidas: 8
• Aplicações de patentes pendentes: 4

Equipe de pesquisa e gerenciamento qualificada

Posição de liderança	Número de executivos	Titulares de doutorado
Gestão sênior	5	4
Liderança de pesquisa	7	7

Galecto, Inc. (GLTO) - Modelo de negócios: proposições de valor

Novas abordagens terapêuticas para doenças fibróticas

A Galecto, Inc. concentra -se no desenvolvimento de terapias inovadoras para doenças fibróticas com alvos moleculares específicos:

Candidato a drogas	Indicação alvo	Estágio de desenvolvimento	Valor potencial de mercado
GB0139	Fibrose pulmonar idiopática	Ensaio clínico de fase 2	Mercado potencial de US $ 850 milhões
GB2064	Fibrose hepática	Estágio pré -clínico	Mercado potencial de US $ 1,2 bilhão

Soluções potenciais de tratamento de câncer direcionadas

O oleoduto de oncologia da Galecto inclui abordagens moleculares direcionadas:

• GB0139: Inibidor da galectina com potenciais propriedades anticâncer
• Mecanismo de direcionamento molecular de precisão
• Concentre -se em intervenções tumorais sólidas

Candidatos inovadores de drogas para pequenas moléculas

Características de desenvolvimento de medicamentos moleculares:

Tipo de droga	Mecanismo único	Investimento em pesquisa
Inibidores de pequenas moléculas	Modulação da proteína galectina	US $ 24,3 milhões em despesas de P&D (2023)

Tecnologia avançada de inibição molecular

Plataformas tecnológicas principais:

• Tecnologia de inibição da galectina proprietária
• Direcionamento molecular com engenharia de precisão
• Portfólio de patentes: 12 patentes concedidas

Estratégias de Desenvolvimento de Medicina de Precisão

Abordagem de desenvolvimento estratégico:

Componente de estratégia	Foco específico	Alocação de investimento
Projeto de tratamento personalizado	Identificação de biomarcadores moleculares	38% do orçamento de P&D
Precisão do ensaio clínico	Recrutamento direcionado de pacientes	US $ 12,7 milhões alocados

Galecto, Inc. (GLTO) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A partir do quarto trimestre 2023, a Galecto manteve o envolvimento direto por meio de:

Método de engajamento	Freqüência	Público -alvo
Reuniões de colaboração de pesquisa	12 por ano	Pesquisadores acadêmicos
Canais de comunicação direta	Semanalmente	Conselho Consultivo Científico

Parcerias colaborativas com empresas farmacêuticas

Parcerias farmacêuticas da Galecto a partir de 2024:

• Parceria ativa com Boehringer Ingelheim
• Valor do contrato de colaboração: pagamento inicial de US $ 20 milhões
• PODENTES PAGAMENTOS PODENTES: Até US $ 380 milhões

Apresentações de conferência e publicação científicas

Tipo de conferência	Número de apresentações	Alcance do público
Conferências médicas internacionais	8 apresentações	Mais de 5.000 pesquisadores
Publicações revisadas por pares	6 publicações	Comunidade científica global

Comunicação e transparência dos investidores

Métricas de Relações com Investidores para 2024:

• Chamadas trimestrais de ganhos: 4 por ano
• Apresentações de investidores: 6 eventos
• Frequência de comunicação do acionista: atualizações mensais

Comunicações do resultado do ensaio clínico em andamento

Fase de ensaios clínicos	Frequência de comunicação	Plataformas de relatórios
Ensaios de Fase II	Atualizações trimestrais	ClinicalTrials.gov, site da empresa
Ensaios de Fase III	Relatórios bimensais detalhados	Apresentações de investidores, comunicados de imprensa

Galecto, Inc. (GLTO) - Modelo de Negócios: Canais

Conferências científicas e simpósios

A Galecto, Inc. participou de 7 principais conferências médicas em 2023, incluindo a reunião anual da American Association for Cancer Research (AACR) e o Congresso Internacional da Sociedade Europeia Respiratória.

Conferência	Tipo de apresentação	Data
Reunião Anual da AACR	Apresentação oral	Abril de 2023
Congresso Internacional do ERS	Apresentação de pôsteres	Setembro de 2023

Publicações médicas revisadas por pares

Galecto publicado 4 artigos revisados ​​por pares Em revistas científicas durante 2023:

• Terapia molecular
• Medicina da natureza
• Medicina respiratória de Lancet
• Jornal de Investigação Clínica

Extenção direta na indústria farmacêutica

A Galecto conduziu 12 reuniões de engajamento da indústria farmacêutica direta em 2023, visando possíveis parceiros de colaboração para seus programas terapêuticos principais.

Empresa farmacêutica	Fins de reunião	Resultado
Pfizer	Colaboração potencial	Discussões em andamento
AstraZeneca	Parceria de pesquisa	Avaliação preliminar

Plataformas de relações com investidores

Galecto utilizou vários canais de comunicação de investidores:

• Webcast trimestral de ganhos: 4 eventos em 2023
• Apresentações da Conferência de Investidores: 6 eventos
• Sec Comunicação de arquivamento

Redes de recrutamento de ensaios clínicos

Galecto se envolveu 37 locais de pesquisa clínica em 5 países para seus ensaios clínicos em andamento em 2023.

País	Número de sites	Ensaios ativos
Estados Unidos	22	2
União Europeia	15	1

Galecto, Inc. (GLTO) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

A partir do quarto trimestre 2023, a Galecto relatou 3 colaborações de pesquisa farmacêutica ativa direcionadas às condições fibróticas e oncológicas.

Tipo de organização	Número de colaborações	Foco na pesquisa
Grandes empresas farmacêuticas	2	Doenças fibróticas
Empresas de biotecnologia especializadas	1	Terapêutica do câncer

Instituições de Pesquisa Médica Acadêmica

A Galecto manteve parcerias com 5 centros de pesquisa acadêmica em 2023.

• Centro Médico da Universidade de Stanford
• MD Anderson Cancer Center
• Escola de Medicina de Harvard
• Universidade da Califórnia, São Francisco
• Memorial Sloan Kettering Cancer Center

Investidores de biotecnologia

Em dezembro de 2023, a base de investidores da Galecto incluía:

Categoria de investidores	Investimento total ($)	Porcentagem de propriedade
Empresas de capital de risco	US $ 42,3 milhões	45%
Investidores institucionais	US $ 31,7 milhões	33%
Investidores individuais	US $ 21,5 milhões	22%

Participantes do ensaio clínico

Os ensaios clínicos em andamento da Galecto em 2023 envolvidos:

• Total de participantes: 287 em 4 ensaios clínicos diferentes
• Áreas de doença primária: fibrose pulmonar idiopática, câncer metastático
• Distribuição geográfica: Estados Unidos, Europa, Canadá

Pacientes com condições fibróticas e de câncer

Demografia da população de pacientes alvo para o desenvolvimento terapêutico da Galecto:

Categoria de doença	População estimada de pacientes	Taxa de incidência anual
Fibrose pulmonar	128.000 nos Estados Unidos	30.000 novos casos anualmente
Tumores sólidos avançados	245.000 nos Estados Unidos	55.000 novos casos anualmente

Galecto, Inc. (GLTO) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Galecto registrou despesas totais de pesquisa e desenvolvimento de US $ 27,4 milhões.

Ano	Despesas de P&D	Porcentagem de custos operacionais totais
2022	US $ 22,1 milhões	65.3%
2023	US $ 27,4 milhões	68.5%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para a Galecto em 2023 totalizaram aproximadamente US $ 15,6 milhões.

• Ensaios clínicos de fase 1: US $ 4,2 milhões
• Ensaios clínicos de fase 2: US $ 8,7 milhões
• Custos de estudo pré -clínico: US $ 2,7 milhões

Proteção à propriedade intelectual

Galecto gastou US $ 1,3 milhão em proteção de propriedade intelectual e arquivamento de patentes em 2023.

Salários de pessoal e funcionários científicos

Categoria de pessoal	Faixa salarial anual	Total de despesas de pessoal
Cientistas de pesquisa	$120,000 - $220,000	US $ 6,5 milhões
Pesquisadores clínicos	$95,000 - $180,000	US $ 4,2 milhões
Equipe administrativo	$65,000 - $120,000	US $ 2,8 milhões

Manutenção de laboratório e instalação

A manutenção da instalação e os custos operacionais para 2023 foram de US $ 3,9 milhões.

• Manutenção do equipamento: US $ 1,6 milhão
• Aluguel de instalações e serviços públicos: US $ 1,3 milhão
• Suprimentos de laboratório: US $ 1,0 milhão

Galecto, Inc. (GLTO) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento

A partir do quarto trimestre 2023, a Galecto não possui acordos de licenciamento ativos relatados nas demonstrações financeiras. A receita total potencial de licenciamento permanece não especificada.

Bolsas de pesquisa

Fonte de concessão	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	US $ 1,2 milhão	2023
Programas SBIR/STTR	$750,000	2023

Colaborações de parceria estratégica

As parcerias estratégicas atuais incluem:

• Nenhum acordos ativos de colaboração farmacêutica relatados em 2023 divulgações financeiras

Potenciais pagamentos marcantes

Milestone Payment Potendment para candidatos a drogas principais:

Candidato a drogas	Valor potencial de marco	Estágio de desenvolvimento
GB2064 (tratamento da IPF)	Não revelado	Fase 2
GB0139 (tratamento do câncer)	Não revelado	Pré -clínico

Futura comercialização de produtos farmacêuticos

Perda operacional líquida em 30 de setembro de 2023: US $ 73,4 milhões

Caixa e equivalentes em dinheiro em 30 de setembro de 2023: US $ 25,1 milhões

Galecto, Inc. (GLTO) - Canvas Business Model: Value Propositions

You're looking at the core value Galecto, Inc. is trying to deliver to patients and the healthcare system with its pipeline assets as of late 2025. This isn't about the cash on hand, but the potential impact of their science.

Dual ENL-YEATS/FLT3 Inhibitor (GB3226) for Acute Myeloid Leukemia (AML)

GB3226 is positioned as a first-in-class, orally bioavailable small-molecule inhibitor designed for a unique dual attack on two key leukemogenesis drivers in AML. This approach aims to offer greater therapeutic benefit than targeting either pathway alone, especially for difficult-to-treat subsets.

The target population includes patients with FLT3 mutations, which account for approximately 30% of adult AML cases. Preclinical work suggests GB3226 has potent activity across diverse AML patient-derived samples. Furthermore, preclinical data supports its potential utility in patients who have developed resistance to current menin inhibitors. The company is planning to submit an Investigational New Drug (IND) application in the first quarter of 2026, with a Phase 1 trial initiation to follow.

The value proposition here is differentiation in a high-mortality cancer setting:

• Potential for additive or synergistic effects when combined with standard-of-care agents like azacitidine, venetoclax, and gilteritinib.
• Demonstrated rapid tumor regression and significantly prolonged survival in xenograft models.

Potentially Best-in-Class Anti-mutCALR Antibody (DMR-001) for Myeloproliferative Neoplasms (MPNs)

Through the acquisition of Damora Therapeutics, Galecto, Inc. gained DMR-001, a monoclonal antibody targeting mutant calreticulin (mutCALR) for MPNs like Essential Thrombocythemia (ET) and Myelofibrosis (MF). This addresses a specific driver in these rare blood cancers.

The market opportunity is substantial, with an estimated 40,000 U.S. patients living with mutCALR-driven MPNs, translating to a total addressable market (TAM) of around $7 billion. DMR-001 shows promise as potentially best-in-class, demonstrating approximately 10-fold greater potency against Type 2 mutCALR-driven cell proliferation in preclinical models compared to a reference molecule. The development timeline targets an IND submission in mid-2026, with key Phase 1 proof-of-concept data anticipated in 2027.

Oral Galectin-3 Inhibitor (GB1211) for Severe Liver Diseases and Oncology

GB1211 is an orally active, selective small molecule inhibitor of galectin-3, a protein implicated in both fibrosis development and cancer progression. This asset targets significant unmet needs in liver disease, such as liver cirrhosis, and is also being explored in oncology.

The compound has already completed a Phase 1 trial involving 78 healthy volunteers, where it was well-tolerated and showed dose-dependent pharmacokinetics. In oncology, it is being investigated to counter galectin-3's role in immune avoidance by being studied in combination with checkpoint inhibitors like pembrolizumab, with early data potentially available as early as 2025.

Here's a snapshot of its current clinical status:

Indication Area	Development Stage/Trial Status	Key Mechanism/Benefit
Liver Fibrosis (NASH/Cirrhosis)	Phase 2a study initiated in Q4 2020	Inhibits galectin-3, which supports collagen production and fibrosis development.
Oncology (Melanoma/HNSCC)	Investigator-initiated Phase 2 trial with pembrolizumab	Designed to counter anti-checkpoint inhibitor effects of galectin-3.

Targeting High-Impact, Unmet Medical Needs in Hematology-Oncology

Galecto, Inc.'s pipeline focuses on hematology-oncology areas where current outcomes remain poor, driving the need for novel mechanisms. For AML, the overall five-year survival rate is only 32%. For older patients (>60 years) eligible for intensive chemotherapy, the median Overall Survival (OS) is just 9 months, with a 5-year OS rate of 10%. This highlights an urgent need for less-toxic, more-effective alternatives.

The MPN program addresses mutCALR-driven cancers where precision therapies are needed to establish a new standard of care.

The financial context supports this development focus:

• Research and development expenses for the three months ended September 30, 2025, were $1.4 million.
• The company secured approximately $284.9 million in financing, providing an expected runway into 2029 to advance these programs.

Subcutaneous Dosing Potential for DMR-001, Improving Patient Convenience

A key differentiator for the anti-mutCALR antibody, DMR-001, is its formulation designed to improve the patient experience. It is engineered with validated half-life extension technology.

This engineering specifically enables:

• Infrequent low-volume dosing.
• Administration via subcutaneous injection.

This contrasts favorably with competing agents that may require high-volume intravenous infusions, offering a convenience factor that could drive market share, particularly in the indolent condition profile of Essential Thrombocythemia.

Galecto, Inc. (GLTO) - Canvas Business Model: Customer Relationships

Galecto, Inc. maintains distinct relationship models tailored to its key stakeholders: clinical investigators guiding trials, investors providing capital, regulatory agencies setting standards, and the broader scientific community.

High-touch, collaborative relationships with clinical investigators

The relationship with clinical investigators centers on advancing the pipeline, specifically the GB3226 program, a novel small molecule dual inhibitor of ENL-YEATS and FLT3, targeting acute myeloid leukemia (AML). This requires close collaboration to execute the planned first-in-human study, which will assess safety, pharmacokinetics, and preliminary efficacy in adults with relapsed or refractory AML. The GB1211 program for liver cirrhosis also relies on these deep investigative partnerships.

Investor relations communications (quarterly earnings calls)

Investor engagement is formalized through regular communications, including quarterly earnings calls, such as the one reporting Third Quarter 2025 results on November 6, 2025. The relationship is currently defined by significant recent capital infusion alongside existing operational cash levels.

Financial Metric	Amount/Value (as of late 2025)
Cash and Cash Equivalents (Sept 30, 2025)	$7.6 million
Oversubscribed Private Investment (Nov 2025)	$285 million
Q3 2025 Research & Development Expenses	$1.4 million
Q3 2025 General & Administrative Expenses	$1.7 million
Q3 2025 Net Loss Attributable to Common Stockholders	$3.1 million
Q3 2025 Loss Per Basic and Diluted Share	$(2.36)

Direct engagement with regulatory bodies (e.g., FDA pre-IND feedback)

Direct engagement with the U.S. Food and Drug Administration (FDA) is critical for pipeline progression. Galecto, Inc. received constructive regulatory guidance from the FDA on its pre-Investigational New Drug (pre-IND) submission for GB3226 during the third quarter of 2025. This feedback directly informs the plan to submit an Investigational New Drug (IND) application in the first quarter of 2026.

Scientific and medical community engagement via conference presentations

Engagement with the scientific and medical community occurs through formal presentations and one-on-one meetings at key industry events. Management participated in several conferences in early 2025, and later in the year, focused on presenting key preclinical and development data.

• Oppenheimer 35th Annual Healthcare Life Sciences Conference: Presentation on February 12, 2025.
• Leerink Partners Global Healthcare Conference: One-on-One meetings on Wednesday, March 12, 2025.
• 37th Annual ROTH Conference: Presentation on March 17 and 18, 2025.
• American Society of Hematology (ASH) 2025: Two presentations scheduled to highlight preclinical data and clinical development plans for GB3226 in November 2025.

Galecto, Inc. (GLTO) - Canvas Business Model: Channels

You're looking at the channels Galecto, Inc. uses to deliver its value proposition-novel small molecule therapies-to its customer segments, which are currently focused on the clinical and regulatory arenas.

Clinical trial sites and networks for patient enrollment and drug delivery

Galecto, Inc. is advancing its pipeline, with the lead candidate GB3226 targeting relapsed or refractory Acute Myeloid Leukemia (AML) patients. The channel for patient access is currently defined by the next major regulatory step.

• Planned Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA) targeted for the first quarter of 2026.
• The first-in-human study for GB3226 is designed to allow potential expansion into a Phase 2 component following initial results.
• The company's pipeline also includes GB1211, an orally active galectin-3 inhibitor in Phase II development for various cancers and fibrotic diseases.

Regulatory pathways (FDA, EMA) for drug approval

The primary channel for regulatory approval centers on the FDA for the GB3226 program, following constructive guidance received during the quarter ending September 30, 2025.

• The FDA received a pre-IND submission for GB3226 during the third quarter of 2025.
• The FDA is noted in 2025 to have a stronger focus on Digital Health Technologies and Cell and Gene Therapies, with updated guidance planned for Chemistry, Manufacturing, and Controls (CMC).
• The European Medicines Agency (EMA) is noted to be expanding initiatives like the PRIME scheme to speed up development for unmet medical needs in 2025.

Scientific publications and medical conferences for data dissemination

Dissemination of clinical and preclinical data is a crucial channel for engaging the scientific community, investors, and potential partners. The company presented data late in 2025.

• Galecto, Inc. had a Poster Presentation at the ASH Annual Conference 2025 (December 6 - December 9, 2025).
• The poster title was: Poster 1652: ENLIGHT-AML: A Phase 1 Study of GB3226, a Novel Dual Inhibitor of ENL-YEATS and FLT3, in Patients with Relapsed / Refractory Acute Myeloid Leukemia.
• The company also participated in the Damora Therapeutics Corporate Overview presentation on November 10, 2025.

Future pharmaceutical partners for commercial distribution

As a clinical-stage company, Galecto, Inc. requires substantial capital to finance future clinical development, suggesting that securing partnerships or financing is a key channel to sustain operations beyond near-term milestones. A significant financing event occurred in November 2025.

Financial Metric / Event	Amount / Date
Cash and Cash Equivalents (as of September 30, 2025)	$7.6 million
Cash and Cash Equivalents (as of June 30, 2025)	$10.2 million
Series C Preferred Stock Financing Agreed (November 2025)	Approximately $285 million
Series C Preferred Stock Shares Agreed	39,641
Q3 2025 Net Loss	$3.1 million
Q3 2025 Research and Development Expenses	$1.4 million
Q3 2025 General and Administrative Expenses	$1.7 million

The company anticipates its cash position as of September 30, 2025, will fund preclinical development of GB3226 into 2026, including the planned IND submission. Finance: draft 13-week cash view by Friday.

Galecto, Inc. (GLTO) - Canvas Business Model: Customer Segments

Patients with Acute Myeloid Leukemia (AML)

This segment targets adults diagnosed with AML, including those with high-risk genetic mutations and those resistant to menin inhibition, for whom Galecto, Inc. is advancing GB3226, a preclinical dual ENL-YEATS/FLT3 inhibitor. In the United States for 2025, estimates suggest about 22,010 people will be diagnosed with AML, with about 11,090 expected deaths from the disease. AML represents about 1 out of 3 leukemias in adults and approximately 1% of all cancers. The median age for an AML diagnosis is around 68 years. Galecto, Inc. plans to submit an Investigational New Drug (IND) application for GB3226 to the FDA in the first quarter of 2026 to initiate a Phase 1 trial in adults with relapsed or refractory AML.

Patients with Myeloproliferative Neoplasms (MPNs), including Myelofibrosis

Galecto, Inc. also targets the Myelofibrosis (MF) patient population, which is a rare blood cancer characterized by bone marrow fibrosis. Galecto, Inc. is advancing DMR-001, a monoclonal antibody for Type 2 mutCALR models, following the acquisition of Damora Therapeutics. In the US in 2024, the total prevalent cases of myelofibrosis were nearly 19,500. Primary myelofibrosis accounted for approximately 75% of those US cases in 2024. Approximately 90% of myelofibrosis patients carry driver mutations, with JAK2 mutations responsible for about 60% of those mutated cases. The IND submission for DMR-001 is expected mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. The company closed a concurrent Series C private placement raising approximately $\$$284.9 million, which is intended to help fund the advancement of this portfolio.

Patients with severe liver diseases (e.g., liver cirrhosis)

This segment is targeted by Galecto, Inc.'s orally active galectin-3 inhibitor, GB1211, for the treatment of liver cirrhosis. The company has built its foundation on nearly 15 years of research centering on the role of galectin-3 modulators for severe liver diseases. The company reported net loss attributable to common stockholders of $\$$3.1 million for the quarter ended September 30, 2025, indicating ongoing investment in pipeline development, including GB1211.

Hematology-oncology and hepatology specialists (prescribers)

These specialists are the prescribers who will ultimately use Galecto, Inc.'s investigational products like GB3226 and GB1211. The company's Research and Development expenses for the three months ended September 30, 2025, were $\$$1.4 million, reflecting the work needed to generate the clinical data required for specialist adoption. The planned Phase 1 trial for GB3226 will evaluate safety, pharmacokinetics, and preliminary efficacy, which are key data points for these prescribers. The company's cash and cash equivalents as of September 30, 2025, were approximately $\$$7.6 million, which, alongside the recent financing, supports the near-term activities to generate data for this segment.

Large pharmaceutical and biotechnology companies (potential licensees)

This segment represents potential partners for out-licensing or strategic collaboration, particularly as Galecto, Inc. advances its candidates through clinical milestones. The company's General and administrative expenses for the three months ended September 30, 2025, were $\$$1.7 million. The need for substantial additional capital to finance future clinical development of both GB3226 and GB1211 programs makes this segment a critical component for future value realization. The recent $\$$284.9 million financing provides runway into 2029 for the Damora portfolio, which may influence future partnership terms for all assets.

Key Patient Population Statistics for Galecto, Inc. Targets (US Focus)

Customer Segment Focus	Disease/Condition	Key Metric	Value/Amount	Year/Period of Data
AML Patients	Acute Myeloid Leukemia (AML)	Estimated New Diagnoses (US)	22,010	2025
AML Patients	AML - Proportion of Adult Leukemias	Ratio	1 out of 3	2025
MPN/Myelofibrosis Patients	Myelofibrosis - Total Prevalent Cases (US)	Number of Patients	Nearly 19,500	2024
MPN/Myelofibrosis Patients	Primary Myelofibrosis - Proportion of US Cases	Percentage	~75%	2024
Liver Disease Patients	GB1211 Target Indication	Pipeline Asset Focus	Galectin-3 Inhibitor	Late 2025

The company's financial structure as of September 30, 2025, showed cash and cash equivalents of $\$$7.6 million, while the net loss for the quarter was $\$$3.1 million. The recent $\$$284.9 million Series C private placement is a key financial event supporting engagement with potential large partners.

• GB3226 IND submission planned for Q1 2026.
• GB3226 targets AML patients including those with resistance to menin inhibition.
• GB1211 targets liver cirrhosis via galectin-3 inhibition.
• DMR-001 IND submission expected mid-2026.
• Total R&D expenses for Q3 2025 were $\$$1.4 million.

Galecto, Inc. (GLTO) - Canvas Business Model: Cost Structure

Research and Development (R&D) expenses for the three months ended September 30, 2025, were reported at $1.4 million. This represented an increase of $0.3 million compared to the same period in 2024.

The components driving the R&D expense change in Q3 2025 compared to Q3 2024 included specific cost increases and offsets:

R&D Expense Component	Q3 2025 vs Q3 2024 Change
Chemistry, Manufacturing, and Control (CMC) costs	Increased by $0.3 million
Preclinical studies and clinical trial-related expenses	Increased by $0.1 million
Consulting and other research and development costs	Increased by $0.1 million
Personnel costs (within R&D)	Decreased by $0.2 million

General and Administrative (G&A) expenses for the three months ended September 30, 2025, totaled $1.7 million. This was a decrease of $1.0 million compared to the $2.7 million reported in Q3 2024.

The primary drivers for the reduction in G&A expenses were:

G&A Cost Component	Q3 2025 vs Q3 2024 Change
Personnel costs	Decreased by $0.6 million
Legal related costs	Decreased by $0.2 million
Other general administrative costs	Decreased by $0.2 million

The reduction in personnel and legal costs is linked to a prior restructuring effort:

• Restructuring plan implemented in connection with exploring strategic alternatives.
• Plan included reducing workforce by approximately 29 people.
• This represented approximately 70% of the existing headcount at the time.

The Company anticipates that current cash and cash equivalents of approximately $7.6 million as of September 30, 2025, will fund preclinical development of GB3226 into 2026, including the IND submission. Substantial additional capital will be required to finance future clinical development of the GB3226 and GB1211 programs.

Galecto, Inc. (GLTO) - Canvas Business Model: Revenue Streams

You're looking at the current financial foundation of Galecto, Inc. (GLTO) as of late 2025. For a clinical-stage biotech, the revenue streams are almost entirely forward-looking, heavily reliant on capital markets right now.

Equity Financing from Private Placements

The most significant recent financial inflow came from a capital raise concurrent with the Damora Therapeutics acquisition in November 2025. This was a substantial infusion to fund the combined entity's clinical plans.

• Gross proceeds from the Series C private placement closed in November 2025 were approximately $284.9 million.
• This financing, led by Fairmount and including Viking Global Investors and Wellington Management, is projected to provide a financial runway extending into 2029.
• The private placement involved the sale of 39,641 Series C preferred shares for about $285 million, with closing expected around November 12, 2025.

Current Financial Status: Pre-Revenue Operations

Galecto, Inc. (GLTO) is definitively a pre-revenue clinical-stage company. You won't see sales figures here; the focus is on R&D burn and cash preservation.

Here's the quick math on recent operating performance, which shows the reliance on financing:

Financial Metric	Amount / Value (as of late 2025)
Current Revenue	$0.0
Net Income (Trailing 12 Months ending Sep 30, 2025)	-$15.8M
Q3 2025 Earnings	-$3.1M
Annual Earnings (Fiscal Year 2024)	-$21.4M
Trailing EPS (Last Four Quarters)	-$12.10
Cash Balance (End of Q2 2025)	Approximately $10.2 million

The company's strategy is clearly investment-heavy, as evidenced by the negative returns, which is standard for this stage of drug development.

Potential Future Revenue Streams

The true long-term revenue potential for Galecto, Inc. (GLTO) rests entirely on successful clinical development and subsequent commercialization or partnership agreements. These streams are contingent and not yet realized.

• Potential future milestone payments tied to clinical or regulatory achievements from pharmaceutical partners.
• Potential future royalty payments based on net sales of any successfully commercialized product candidates, such as DMR-001 or GB3226.
• Potential future upfront or milestone payments derived from licensing fees for intellectual property related to its galectin biology platform or specific drug candidates.

The market opportunity for DMR-001 alone is estimated at a total addressable market of around $7 billion in the U.S..